IN2014DN09348A - - Google Patents

Info

Publication number
IN2014DN09348A
IN2014DN09348A IN9348DEN2014A IN2014DN09348A IN 2014DN09348 A IN2014DN09348 A IN 2014DN09348A IN 9348DEN2014 A IN9348DEN2014 A IN 9348DEN2014A IN 2014DN09348 A IN2014DN09348 A IN 2014DN09348A
Authority
IN
India
Prior art keywords
compounds
disorders
substituents
useful
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Matthew C Lucas
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN09348(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2014DN09348A publication Critical patent/IN2014DN09348A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IN9348DEN2014 2012-06-20 2013-06-17 IN2014DN09348A (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661961P 2012-06-20 2012-06-20
PCT/EP2013/062461 WO2013189864A1 (en) 2012-06-20 2013-06-17 N-alkyltriazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
IN2014DN09348A true IN2014DN09348A (hr) 2015-07-17

Family

ID=48628667

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9348DEN2014 IN2014DN09348A (hr) 2012-06-20 2013-06-17

Country Status (22)

Country Link
US (1) US9321738B2 (hr)
EP (1) EP2864300A1 (hr)
JP (1) JP2015520202A (hr)
KR (1) KR20150021057A (hr)
CN (1) CN104411692A (hr)
AU (1) AU2013279512A1 (hr)
BR (1) BR112014030685A2 (hr)
CA (1) CA2869541A1 (hr)
CL (1) CL2014003243A1 (hr)
CO (1) CO7131358A2 (hr)
CR (1) CR20140525A (hr)
EA (1) EA201492285A1 (hr)
HK (1) HK1206342A1 (hr)
IL (1) IL236088A0 (hr)
IN (1) IN2014DN09348A (hr)
MA (1) MA37764A1 (hr)
MX (1) MX2014014710A (hr)
PE (1) PE20142448A1 (hr)
PH (1) PH12014502789A1 (hr)
SG (1) SG11201407220YA (hr)
UA (1) UA109868C2 (hr)
WO (1) WO2013189864A1 (hr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014001732A (es) 2011-08-15 2014-07-09 Intermune Inc Antagonistas del receptor de acido lisofosfatidico.
EP2864301A1 (en) * 2012-06-20 2015-04-29 F. Hoffmann-La Roche AG N-aryltriazole compounds as lpar antagonists
SG10201803833WA (en) 2013-03-15 2018-06-28 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
JP6579103B2 (ja) 2014-06-27 2019-09-25 宇部興産株式会社 ハロゲン置換へテロ環化合物の塩
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2019126093A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as lpa antagonists
AU2018388482A1 (en) 2017-12-19 2020-07-30 Bristol-Myers Squibb Company Pyrazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
WO2019126086A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as lpa antagonists
EA202091505A1 (ru) * 2017-12-19 2020-09-22 Бристол-Маерс Сквибб Компани Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
CN112189010A (zh) 2017-12-19 2021-01-05 百时美施贵宝公司 作为lpa拮抗剂的三唑n-连接的氨基甲酰基环己基酸
US11352345B2 (en) 2017-12-19 2022-06-07 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as LPA antagonists
US11447475B2 (en) 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
KR20200101957A (ko) * 2017-12-19 2020-08-28 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 이속사졸 o-연결된 카르바모일 시클로헥실 산
EP3728196B1 (en) 2017-12-19 2023-04-05 Bristol-Myers Squibb Company Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
CN112074515A (zh) * 2017-12-19 2020-12-11 百时美施贵宝公司 作为lpa拮抗剂的环己基酸异噁唑唑类
ES2944304T3 (es) 2017-12-19 2023-06-20 Bristol Myers Squibb Co Pirazol azinas de ácido ciclohexílico como antagonistas de LPA
CN117024420A (zh) * 2017-12-29 2023-11-10 生物马林药物股份有限公司 用于疾病治疗的乙醇酸氧化酶抑制剂
US20220041572A1 (en) * 2018-09-18 2022-02-10 Bristol-Myers Squibb Company Cycloheptyl acids as lpa antagonists
EP3853232B1 (en) * 2018-09-18 2023-03-01 Bristol-Myers Squibb Company Oxabicyclo acids as lpa antagonists
KR20210061383A (ko) * 2018-09-18 2021-05-27 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로펜틸 산
EP4058144A1 (en) 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
JP7490088B2 (ja) 2020-06-03 2024-05-24 ギリアード サイエンシーズ, インコーポレイテッド Lpa受容体アンタゴニスト及びその使用
EP4161936A1 (en) 2020-06-03 2023-04-12 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2022240879A1 (en) 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與lpa受體活性相關的病狀的化合物及組合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011159550A2 (en) 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
PE20140879A1 (es) * 2010-12-07 2014-08-06 Amira Pharmaceuticals Inc Antagonistas del receptor de acido lisofosfatidico para el tratamiento de fibrosis
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
MX2014001732A (es) 2011-08-15 2014-07-09 Intermune Inc Antagonistas del receptor de acido lisofosfatidico.

Also Published As

Publication number Publication date
EA201492285A1 (ru) 2015-04-30
CR20140525A (es) 2015-01-12
BR112014030685A2 (pt) 2017-06-27
CL2014003243A1 (es) 2015-03-20
UA109868C2 (ru) 2015-10-12
MA37764A1 (fr) 2016-01-29
EP2864300A1 (en) 2015-04-29
US9321738B2 (en) 2016-04-26
CO7131358A2 (es) 2014-12-01
AU2013279512A1 (en) 2014-10-16
HK1206342A1 (en) 2016-01-08
CN104411692A (zh) 2015-03-11
KR20150021057A (ko) 2015-02-27
PE20142448A1 (es) 2015-01-28
JP2015520202A (ja) 2015-07-16
US20150133511A1 (en) 2015-05-14
SG11201407220YA (en) 2014-12-30
MX2014014710A (es) 2015-03-04
PH12014502789A1 (en) 2015-02-09
IL236088A0 (en) 2015-02-01
CA2869541A1 (en) 2013-12-27
WO2013189864A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
IN2014DN09352A (hr)
IN2014DN09348A (hr)
IN2014DN09347A (hr)
PH12016500024A1 (en) Bromodomain inhibitor
IN2014MN02598A (hr)
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
IN2015DN01119A (hr)
EP4275756A3 (en) Bipyrazole derivatives as jak inhibitors
IN2014DN09434A (hr)
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
MX2016002794A (es) Compuestos antiproliferativos.
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
IN2014DN06869A (hr)
MX340574B (es) Imidazo pirazinas.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
IN2013DN02555A (hr)
WO2015002755A3 (en) Compounds for the treatment of malaria
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
CA2905957C (en) Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders
MX2014001862A (es) 5-cicloalquil-o 5-heterociclil-nicotinamidas.